$254 Million is the total value of Alerce Investment Management, L.P.'s 7 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMWL | New | AMERICAN WELL CORPcl a | $159,599,000 | – | 6,300,773 | +100.0% | 62.85% | – |
| ANNX | New | ANNEXON INC | $48,933,000 | – | 1,954,978 | +100.0% | 19.27% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $13,476,000 | – | 2,227,500 | +100.0% | 5.31% | – |
| AKBA | New | AKEBIA THERAPEUTICS INC | $13,027,000 | – | 4,652,561 | +100.0% | 5.13% | – |
| ALRN | New | AILERON THERAPEUTICS INC | $7,914,000 | – | 7,609,449 | +100.0% | 3.12% | – |
| ARPO | New | AERPIO PHARMACEUTICALS INC | $5,509,000 | – | 5,621,835 | +100.0% | 2.17% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $5,469,000 | – | 126,270 | +100.0% | 2.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMERICAN WELL CORP | 12 | Q3 2023 | 62.9% |
| ANNEXON INC | 12 | Q3 2023 | 35.9% |
| AKEBIA THERAPEUTICS INC | 12 | Q3 2023 | 31.6% |
| ASSEMBLY BIOSCIENCES INC | 12 | Q3 2023 | 8.7% |
| AADI BIOSCIENCES INC | 9 | Q3 2023 | 24.1% |
| AILERON THERAPEUTICS INC | 8 | Q3 2022 | 14.4% |
| GLOBAL BLOOD THERAPEUTICS IN | 8 | Q3 2022 | 23.4% |
| AILERON THERAPEUTICS INC | 4 | Q3 2023 | 2.3% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 5.2% |
View Alerce Investment Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-04 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-09 |
| 13F-HR | 2021-11-15 |
View Alerce Investment Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.